Reduced ability of hemagglutinin of the CAM-70 measles virus vaccine strain to use receptors CD46 and SLAM

Kato, Seiichi; Ohgimoto, Shinji; Sharma, Luna Bhatta; Kurazono, Sekiko; Ayata, Minoru; Komase, Katsuhiro; Takeda, Makoto; Takeuchi, Kaoru; Ihara, Toshiaki; Ogura, Hisashi

doi:10.1016/j.vaccine.2009.04.010

Cited by 10 publications

(8 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aspartic acids at positions 505 and 507 also interact with SLAM [18], and a mutation at position 505 or 506 allows MV to escape neutralization by MAb-80-II-B2 (Figure 2D) [5,36]. The CAM-70 vaccine strain is not neutralized by MAb-80-II-B2 because it has an amino acid substitution at position 505, and it uses SLAM less efficiently than other strains [37]. A mutant resistant to neutralization by MAb-16-DE6 has acquired a mutation at amino acid position 533, one of the residues that interact with SLAM (Figure 2D) [34,35].…”

Section: Receptor-binding Epitope (Rbe)mentioning

confidence: 99%

Measles Virus Hemagglutinin Protein Epitopes: The Basis of Antigenic Stability

Tahara

Bürckert

Kanou

et al. 2016

Viruses

Self Cite

View full text Add to dashboard Cite

Globally eliminating measles using available vaccines is biologically feasible because the measles virus (MV) hemagglutinin (H) protein is antigenically stable. The H protein is responsible for receptor binding, and is the main target of neutralizing antibodies. The immunodominant epitope, known as the hemagglutinating and noose epitope, is located near the receptor-binding site (RBS). The RBS also contains an immunodominant epitope. Loss of receptor binding correlates with an escape from the neutralization by antibodies that target the epitope at RBS. Another neutralizing epitope is located near RBS and is shielded by an N-linked sugar in certain genotype strains. However, human sera from vaccinees and measles patients neutralized all MV strains with similar efficiencies, regardless of the N-linked sugar modification or mutations at these epitopes. Two other major epitopes exist at a distance from RBS. One has an unstructured flexible domain with a linear neutralizing epitope. When MV-H forms a tetramer (dimer of dimers), these epitopes may form the dimer-dimer interface, and one of the two epitopes may also interact with the F protein. The neutralization mechanisms of antibodies that recognize these epitopes may involve inhibiting the H-F interaction or blocking the fusion cascade after MV-H binds to its receptors.

show abstract

Section: Receptor-binding Epitope (Rbe)mentioning

confidence: 99%

Measles Virus Hemagglutinin Protein Epitopes: The Basis of Antigenic Stability

Tahara

Bürckert

Kanou

et al. 2016

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, p(ϩ)MV323-CAM F did not possess ATG (nt 5449 to 5451) which is found in the CAM-70 F gene. p(ϩ)MV323-CAM H, in which the H gene region of p(ϩ)MV323 was replaced with the corresponding region of the CAM-70 strain, was generated previously (19).…”

Section: Methodsmentioning

confidence: 99%

Contribution of Matrix, Fusion, Hemagglutinin, and Large Protein Genes of the CAM-70 Measles Virus Vaccine Strain to Efficient Growth in Chicken Embryonic Fibroblasts

Sharma

Ohgimoto

Kato

et al. 2009

J Virol

Self Cite

View full text Add to dashboard Cite

“…Moraten and Schwarz are identical in sequence and EZ differs from Moraten/Schwarz at 21 amino acids (8,127,128). Sequences of vaccine strains compared with current WT strains reveal differences in most viral proteins, any of which may contribute to attenuation and no one change or combination of changes has been identified as responsible for attenuation (6,8,36,63,105,127,128,(173)(174)(175).…”

Section: Molecular Determinants Of Attenuationmentioning

confidence: 99%

“…Changes in multiple protein genes (P/C/V, M, F, H, and L) are selected (7,36,60,94,160,168,169,172,173,178,186). Construction of recombinant viruses using the Japanese IC-B WT and CAM-70 vaccine strains has shown that changes in M, F, H, and L all contribute to efficient growth of CAM-70 in CEFs (63,160), but which one or combination of changes alters in vivo virulence has not been identified.…”

Section: Molecular Determinants Of Attenuationmentioning

confidence: 99%

Measles Vaccine

Griffin

2018

Viral Immunology

109

View full text Add to dashboard Cite

Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. The current measles virus (MeV) vaccine was developed empirically by attenuation of wild-type (WT) MeV by in vitro passage in human and chicken cells and licensed in 1963. Additional passages led to further attenuation and the successful vaccine strains in widespread use today. Attenuation is associated with decreased replication in lymphoid tissue, but the molecular basis for this restriction has not been identified. The immune response is age dependent, inhibited by maternal antibody (Ab) and involves induction of both Ab and T cell responses that resemble the responses to WT MeV infection, but are lower in magnitude. Protective immunity is correlated with levels of neutralizing Ab, but the actual immunologic determinants of protection are not known. Because measles is highly transmissible, control requires high levels of population immunity. Delivery of the two doses of vaccine needed to achieve >90% immunity is accomplished by routine immunization of infants at 9-15 months of age followed by a second dose delivered before school entry or by periodic mass vaccination campaigns. Because delivery by injection creates hurdles to sustained high coverage, there are efforts to deliver MeV vaccine by inhalation. In addition, the safety record for the vaccine combined with advances in reverse genetics for negative strand viruses has expanded proposed uses for recombinant versions of measles vaccine as vectors for immunization against other infections and as oncolytic agents for a variety of tumors.

show abstract

Reduced ability of hemagglutinin of the CAM-70 measles virus vaccine strain to use receptors CD46 and SLAM

Cited by 10 publications

References 57 publications

Measles Virus Hemagglutinin Protein Epitopes: The Basis of Antigenic Stability

Measles Virus Hemagglutinin Protein Epitopes: The Basis of Antigenic Stability

Contribution of Matrix, Fusion, Hemagglutinin, and Large Protein Genes of the CAM-70 Measles Virus Vaccine Strain to Efficient Growth in Chicken Embryonic Fibroblasts

Measles Vaccine

Contact Info

Product

Resources

About